{"organizations": [], "uuid": "7caa4c498a57211047bc40db18da84d553c4ce7f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 12, "shares": 12, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/healthNews", "section_title": "Reuters: Health News", "url": "https://www.reuters.com/article/us-gilead-sciences-ema/gileads-three-drug-hiv-regimen-wins-european-panel-approval-idUSKBN1HY1J9", "country": "US", "domain_rank": 408, "title": "Gilead's three-drug HIV regimen wins European panel approval", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-27T14:36:00.000+03:00", "replies_count": 0, "uuid": "7caa4c498a57211047bc40db18da84d553c4ce7f"}, "author": "", "url": "https://www.reuters.com/article/us-gilead-sciences-ema/gileads-three-drug-hiv-regimen-wins-european-panel-approval-idUSKBN1HY1J9", "ord_in_thread": 0, "title": "Gilead's three-drug HIV regimen wins European panel approval", "locations": [], "entities": {"persons": [{"name": "biktarvy", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "gilead", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "shionogi ltd", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "committee for medicinal products for human use", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "gilead sciences inc", "sentiment": "none"}, {"name": "european commission", "sentiment": "none"}, {"name": "viiv healthcare", "sentiment": "none"}, {"name": "glaxosmithkline plc", "sentiment": "none"}, {"name": "chmp", "sentiment": "none"}, {"name": "european medicines agency", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 27, 2018 / 11:36 AM / Updated 7 hours ago Gilead's three-drug HIV regimen wins European panel approval Reuters Staff 2 Min Read\n(Reuters) - Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.\nThe Committee for Medicinal Products for Human Use (CHMP) backed the treatment, Biktarvy, a once-daily tablet that combines two previously approved drugs - emtricitabine, tenofovir alafenamide and a new integrase inhibitor bictegravir.\nThe CHMP opinion sets the stage for a likely approval by the European Commission.\nThe combination, which was approved by the U.S. Food and Drug Administration in February, faced criticism from rival ViiV Healthcare, a joint venture majority-owned by GlaxoSmithKline Plc with Pfizer Inc and Shionogi Ltd.\nThe joint venture filed a lawsuit soon after the U.S. regulator’s approval alleging that Gilead was infringing patents on ViiV’s dolutegravir, a component of the company’s triple-drug HIV treatment Triumeq. Reporting By Justin George Varghese in Bengaluru; Editing by Bernard Orr", "external_links": [], "published": "2018-04-27T14:36:00.000+03:00", "crawled": "2018-04-27T15:14:53.016+03:00", "highlightTitle": ""}